Immunologic Timing and Therapeutic Sequencing of Locoregional Therapy and Immunotherapy in Hepatocellular Carcinoma.
Immune checkpoint inhibitor combinations have improved outcomes in hepatocellular carcinoma, but durable benefit remains uneven and the optimal integration of locoregional therapy is unresolved. Local interventions can release tumor antigens, alter vascular and stromal barriers, and recruit innate and adaptive immune c...